CN100584844C - 咪唑[1,2-c]嘧啶基乙酸衍生物 - Google Patents

咪唑[1,2-c]嘧啶基乙酸衍生物 Download PDF

Info

Publication number
CN100584844C
CN100584844C CN200580010462A CN200580010462A CN100584844C CN 100584844 C CN100584844 C CN 100584844C CN 200580010462 A CN200580010462 A CN 200580010462A CN 200580010462 A CN200580010462 A CN 200580010462A CN 100584844 C CN100584844 C CN 100584844C
Authority
CN
China
Prior art keywords
alkyl
formula
halogen
optionally substituted
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580010462A
Other languages
English (en)
Chinese (zh)
Other versions
CN1938310A (zh
Inventor
连泰威
吉野隆佚
武川由纪
新谷拓哉
杉本宏美
凯文·B·培根
克劳斯·俄拜斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of CN1938310A publication Critical patent/CN1938310A/zh
Application granted granted Critical
Publication of CN100584844C publication Critical patent/CN100584844C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200580010462A 2004-01-31 2005-01-19 咪唑[1,2-c]嘧啶基乙酸衍生物 Expired - Fee Related CN100584844C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002144.6 2004-01-31
EP04002144 2004-01-31

Publications (2)

Publication Number Publication Date
CN1938310A CN1938310A (zh) 2007-03-28
CN100584844C true CN100584844C (zh) 2010-01-27

Family

ID=34814234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580010462A Expired - Fee Related CN100584844C (zh) 2004-01-31 2005-01-19 咪唑[1,2-c]嘧啶基乙酸衍生物

Country Status (23)

Country Link
US (1) US7750014B2 (https=)
EP (1) EP1718649B1 (https=)
JP (1) JP4996257B2 (https=)
KR (1) KR101207428B1 (https=)
CN (1) CN100584844C (https=)
AT (1) ATE433452T1 (https=)
AU (1) AU2005209381B2 (https=)
BR (1) BRPI0507123A (https=)
CA (1) CA2551778C (https=)
CY (1) CY1109274T1 (https=)
DE (1) DE602005014849D1 (https=)
DK (1) DK1718649T3 (https=)
ES (1) ES2326896T3 (https=)
IL (1) IL177083A (https=)
MX (1) MXPA06007674A (https=)
NO (1) NO20063878L (https=)
NZ (1) NZ548396A (https=)
PL (1) PL1718649T3 (https=)
PT (1) PT1718649E (https=)
RU (1) RU2373208C2 (https=)
SI (1) SI1718649T1 (https=)
WO (1) WO2005073234A2 (https=)
ZA (1) ZA200605387B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594280C (en) 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ATE530523T1 (de) 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
CA2681311A1 (en) * 2007-04-13 2008-10-23 Novartis Ag Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
BRPI0817318A2 (pt) 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma.
JP5524847B2 (ja) * 2007-09-25 2014-06-18 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしてのアルキルチオピリミジン
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8541419B2 (en) 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
WO2013131923A1 (de) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituierte azabicyclen und ihre verwendung
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (ko) 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
KR20190103507A (ko) 2018-02-12 2019-09-05 김강민 지하철 혼잡도 알림 시스템
WO2019139462A2 (ko) * 2019-02-21 2019-07-18 엘지전자 주식회사 하차 시점 알림 방법 및 사용자 단말
TW202100015A (zh) 2019-02-28 2021-01-01 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
ES2237470T3 (es) * 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
PL377314A1 (pl) * 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AN ORALLY BIOAVAILABLE SMALL MOLECULEANTAGONIST OF CRTH2,RAMATROBAN(BAYU3405),INHIBITS PROSTAGLANDIN D2-INDUCEDEOSINOPHIL MIGRATION IN VITRO. SUGIMOTO H ET AL.JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,Vol.305 No.1. 2003 *

Also Published As

Publication number Publication date
NZ548396A (en) 2010-06-25
BRPI0507123A (pt) 2007-06-19
CY1109274T1 (el) 2014-07-02
DE602005014849D1 (de) 2009-07-23
IL177083A0 (en) 2006-12-10
ATE433452T1 (de) 2009-06-15
ZA200605387B (en) 2008-05-28
US7750014B2 (en) 2010-07-06
US20090012102A1 (en) 2009-01-08
PL1718649T3 (pl) 2009-11-30
ES2326896T3 (es) 2009-10-21
HK1101969A1 (en) 2007-11-02
CN1938310A (zh) 2007-03-28
IL177083A (en) 2011-10-31
KR20060130187A (ko) 2006-12-18
WO2005073234A2 (en) 2005-08-11
JP2007519659A (ja) 2007-07-19
RU2006131304A (ru) 2008-03-10
EP1718649A2 (en) 2006-11-08
JP4996257B2 (ja) 2012-08-08
CA2551778C (en) 2013-10-22
MXPA06007674A (es) 2006-09-04
KR101207428B1 (ko) 2012-12-04
PT1718649E (pt) 2009-08-06
SI1718649T1 (sl) 2009-10-31
EP1718649B1 (en) 2009-06-10
NO20063878L (no) 2006-10-11
WO2005073234A3 (en) 2005-10-06
DK1718649T3 (da) 2009-08-24
AU2005209381A1 (en) 2005-08-11
CA2551778A1 (en) 2005-08-11
AU2005209381B2 (en) 2011-06-30
RU2373208C2 (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
CN100584844C (zh) 咪唑[1,2-c]嘧啶基乙酸衍生物
EP1633726B1 (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2
WO2019190259A1 (ko) 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
CN101622234A (zh) 适于治疗炎性或变应性病症的二环有机化合物
AU2012221927A1 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
EP2678332A2 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
WO2011062437A2 (ko) 고나도트로핀 방출 호르몬 수용체 길항제, 이의 제조방법 및 이를 함유하는 약제학적 조성물
WO2018004258A1 (ko) 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
WO2019231271A1 (en) Heterocyclic derivatives and use thereof
WO2022250350A1 (ko) 피페리딘디온 유도체
WO2023014022A1 (ko) 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2009096667A4 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물
WO2025147116A1 (en) Novel heterocyclic compounds and pharmaceutical composition comprising the same
HK1101969B (en) Imidazo[1,2-c]pyrimidinylacetic acid derivatives
WO2020263058A1 (ko) 아미노시아노피리딘 유도체 및 그의 용도
WO2023055178A1 (ko) 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물
EP4581026A1 (en) Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same
WO2020080742A1 (en) Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof
WO2019235894A1 (ko) Aimp2-dx2와 k-ras의 결합을 저해하는 화합물을 포함하는 고형암 예방 또는 치료용 조성물 및 aimp2-dx2와 k-ras의 결합을 저해하는 신규 화합물
WO2022270980A1 (ko) Ron 억제제로서의 신규한 우레아 유도체 화합물
WO2021107590A1 (ko) 신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2023177250A1 (ko) 신규 헤테로고리 히스톤 탈아세틸화 효소 저해제 및 이를 포함하는 약학조성물
WO2023244059A1 (en) Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds
WO2017171421A1 (ko) 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
WO2025165094A1 (en) Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101969

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1101969

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100127

Termination date: 20140119